Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review

Research in Developmental Disabilities

Volumn 32, Issue 6, 2011, Pages 2121-2133

  Unwin, Gemma L ^a   Deb, Shoumitro ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atypical antipsychotics; Children; Medication; Problem behaviours

Indexed keywords

PLACEBO; RISPERIDONE;

BEHAVIOR DISORDER; BORDERLINE INTELLIGENCE; CHILD; COGNITIVE DEFECT; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INTELLECTUAL IMPAIRMENT; MULTICENTER STUDY (TOPIC); PARKINSONISM; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; HUMANS; INTELLECTUAL DISABILITY;

EID: 80053622427     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2011.07.031     Document Type: Review

References (46)

1. Aman M.G., Alvarez N., Benefield W., Crismon M.L., Green G., King B.H., et al. Treatment of psychiatric and behavioural problems in mental retardation. American Journal on Mental Retardation 2002, 105:159-228. (Editorial Board).
2. Aman M.G., De Smedt G., Derivan A., Lyons B., Findling R.L. The Risperidone Disruptive Behavior Study Group: Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry 2002, 159:1337-1346.
3. Aman M.G., Gharabawi G. Treatment of behaviour disorders in mental retardation: Report on transitioning to atypical antipsychotics with an emphasis on risperidone. Journal of Clinical Psychiatry 2004, 65:1197-1210.
4. Brylewski J., Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability 2004, The Cochrane Library, Oxford, UK.
5. Buitelaar J.K., van der Gaag R.J., Cohen-Kettenis P., Melman C.T. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry 2001, 62:239-248.
6. Clarke D.J., Kelley S., Thinn K., Corbett J.A. Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in 3 residential settings. Journal of Mental Deficiency Research 1990, 28:229-233.
7. Corrigan P.W. Social skills training in adult psychiatric populations: A meta-analysis. Journal of Behaviour Therapy and Experimental Psychiatry 1991, 22:203-210.
8. De Deyn P.P., Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. European Psychiatry 2006, 21:21-28.
9. Deb S., Chaplin R., Sohanpal S., Unwin G., Soni R., Lenotre L. The effectiveness of mood stabilisers and antiepileptic medication for the management of behaviour problems in adults with intellectual disabilities: A systematic review. Journal of Intellectual Disability Research 2008, 52:107-113.
10. Deb S., Clarke D., Unwin G. Using medication to manage behaviour problems among adults with a learning disability: Quick reference guide 2006, University of Birmingham, The Royal College of Psychiatrists, Mencap, London, UK. http://www.ld-medication.bham.ac.uk/.
11. Deb S., Sohanpal S.K., Soni R., Unwin G., Lenôtre L. The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research 2007, 51:766-777.
12. Deb S., Thomas M., Bright C. Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research 2001, 45:506-514.
13. Deb S., Unwin G. Psychotropic medication for behaviour problems in people with intellectual disability: A review of the current literature. Current Opinion in Psychiatry 2007, 20:461-466.
14. Didden R., Duker P.C., Korzilius H. Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation. American Journal on Mental Retardation 1997, 101:387-399.
15. Einfeld S.L. Systematic management approach to pharmacotherapy for people with learning disabilities. Advances in Psychiatric Treatment 2004, 7:43-49.
16. Einfeld S.L., Tonge B.J. Population prevalence of psychopathology in children and adolescents with intellectual disability. II. Epidemiological findings. Journal of Intellectual Disability Research 1996, 40:99-109.
17. Emerson E., Kiernan C., Alborz A., Reeves D., Mason H., Swarbrick R., et al. Predicting the persistence of severe self-injurious behaviour. Research in Developmental Disabilities 2001, 22:67-75.
18. Emerson E., Kiernan C., Alborz A., Reeves D., Mason H., Swarbrick R., et al. The prevalence of challenging behaviors: A total population study. Research in Developmental Disabilities 2001, 22:77-93.
19. Findling R.L., Aman M.G., Eerdekens M., Derivan A., Lyons B. The Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. American Journal of Psychiatry 2004, 161:677-684.
20. Gagiano C., Read S., Thorpe L., Eerdekens M., Van Hove I. Short- and long term efficacy and safety of risperidone in adults with disruptive behaviour disorders. Psychopharmacology 2005, 179:629-636.
21. Green V., O'Reilly M., Itchon J., Sigafoos J. Persistence of early emerging aberrant behaviour in children with developmental disabilities. Research in Developmental Disabilities 2005, 26:47-55.
22. Grey I.M., Hastings R.P. Evidence-based practices in intellectual disability and behaviour disorders. Current Opinion in Psychiatry 2005, 18:469-475.
23. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] 2011, The Cochrane Collaboration, Available from. http://www.cochrane-handbook.org/, J.P.T. Higgins, S. Green (Eds.).
24. Jadad A.R., Moore R.A., Carroll D., Jenkins C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
25. Jesner O.S., Aref-Adib M., Coren E. Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews 2007, (1). (Art. No.: CD005040). 10.1002/14651858.CD005040.pub2.
26. Matson J.L., Neal D. Psychotropic medication use for challenging behaviours in persons with intellectual disabilities: An overview. Research in Developmental Disabilities 2009, 30:572-586.
27. McGillivray J.A., McCabe M.P. Pharmacological management of challenging behavior of individuals with intellectual disability. Research in Developmental Disabilities 2004, 25:523-537.
28. Oliver-Africano P.C., Dickens S., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Journal of Intellectual Disability Research 2010, 54(1):17-25.
29. Reiss S., Aman M.G. Psychotropic medication and development disabilities: The international consensus handbook 1998, Ohio State University, Columbus, OH.
30. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Risperidone in children with autism and serious behavioural problems. The New England Journal of Medicine 2002, 347:314-321.
31. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry 2005, 162:1361-1369.
32. Scheifes A., Stolker J.J., Egberts A.C.G., Nijman H.L.I., Heerdink E.R. Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for problem behaviours. Journal on Intellectual Disability Research 2010, doi:10.111/j.1365-2788.2010.01353.x.
33. Schroeder S.R., Tessel R.E., Loupe P.S., Stodgell C.J. Severe behavior problems among people with developmental disabilities. Ellis' handbook of mental deficiency, psychological theory, and research 1994, 439-464. Lawrence Erlbaum Associates, New Jersey. 3rd ed. W.E. MacLean (Ed.).
34. Scotti J.R., Evans I.M., Meyer L.H., Walker P. A meta-analysis of intervention research with problem behaviour: Treatment validity and standards of practice. American Journal on Mental Retardation 1991, 96:233-256.
35. Sharma A., Shaw S.R. Efficacy of risperidone in managing maladaptive behaviours for children with autistic spectrum disorder. Journal of Pediatric Health Care 2011, 10.1016/j.pedhc.2011.02.008.
36. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
37. Singh A.N., Matson J.L., Cooper C.L., Dixon D., Sturmey P. The use of risperidone among individuals with mental retardation: Clinically supported or not?. Research in Developmental Disabilities 2005, 26:203-218.
38. Smith S., Branford D., Collacott R., Cooper S.A., McGrother C. Prevalence and cluster typology of maladaptive behaviours in a geographically defined population of adults with learning disabilities. British Journal of Psychiatry 1996, 169:219-227.
39. Snyder R., Turgay A., Aman M., Binder C., Fisman S., Allan C., et al. Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs. Journal of the American Academy of Child & Adolescent Psychiatry 2002, 41:1026-1036.
40. Sohanpal S., Deb S., Thomas C., Soni R., Lenotre L., Unwin G. The effectiveness of antidepressant medication in the management of behavioural problems in adults with intellectual disabilities: A systematic review. Journal of Intellectual Disability Research 2007, 51:750-765.
41. Spreat S., Conroy J., Jones J. Use of psychotropic medication in Oklahoma: A statewide survey. American Journal of Mental Retardation 1997, 102:80-85.
42. Turgay A., Binder C., Snyder R., Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics 2002, 110:e34.
43. Tyrer P., Oliver-Africano P.C., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol and placebo in the treatment of aggressive challenging behaviour in intellectual disability: Randomised controlled trial. Lancet 2008, 371:57-63.
44. Unwin G., Deb S. The use of medication for the management of behaviour problems in adults with intellectual disabilities: A clinicians' consensus survey. American Journal on Mental Retardation 2008, 113(1):19-31.
45. Van Bellinghen M., De Troch C. Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology 2001, 11:5-13.
46. Van den Borre R., Vermote R., Buttiens M., Thiry P., Dierick G., Geutiens J., et al. Risperidone as an add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 1993, 87:167-171.